KR20090009951A - 항치매제를 포함하는 경피 흡수 제제 - Google Patents
항치매제를 포함하는 경피 흡수 제제 Download PDFInfo
- Publication number
- KR20090009951A KR20090009951A KR1020087029711A KR20087029711A KR20090009951A KR 20090009951 A KR20090009951 A KR 20090009951A KR 1020087029711 A KR1020087029711 A KR 1020087029711A KR 20087029711 A KR20087029711 A KR 20087029711A KR 20090009951 A KR20090009951 A KR 20090009951A
- Authority
- KR
- South Korea
- Prior art keywords
- drug
- meth
- transdermal absorption
- dementia
- transdermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000009472 formulation Methods 0.000 title claims abstract description 23
- 230000002205 anti-dementic effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 106
- 229940079593 drug Drugs 0.000 claims abstract description 99
- 239000010410 layer Substances 0.000 claims abstract description 87
- 238000002360 preparation method Methods 0.000 claims abstract description 70
- 229940005524 anti-dementia drug Drugs 0.000 claims abstract description 66
- 238000003860 storage Methods 0.000 claims abstract description 61
- 239000002664 nootropic agent Substances 0.000 claims abstract description 43
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 34
- 239000002250 absorbent Substances 0.000 claims abstract description 31
- 230000002745 absorbent Effects 0.000 claims abstract description 30
- 239000011229 interlayer Substances 0.000 claims abstract description 26
- 229920000642 polymer Polymers 0.000 claims abstract description 17
- 150000001733 carboxylic acid esters Chemical class 0.000 claims abstract description 12
- 230000035515 penetration Effects 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- -1 alkyl sebacic acid ester Chemical class 0.000 claims description 47
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- 229920001577 copolymer Polymers 0.000 claims description 35
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 35
- 239000000194 fatty acid Substances 0.000 claims description 35
- 229930195729 fatty acid Natural products 0.000 claims description 35
- 239000012790 adhesive layer Substances 0.000 claims description 34
- 150000002148 esters Chemical class 0.000 claims description 33
- CXMXRPHRNRROMY-UHFFFAOYSA-N n-Decanedioic acid Natural products OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 31
- 150000001252 acrylic acid derivatives Chemical group 0.000 claims description 29
- 229920000058 polyacrylate Polymers 0.000 claims description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 16
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000000178 monomer Chemical group 0.000 claims description 14
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 7
- 239000004743 Polypropylene Substances 0.000 claims description 7
- 229920001155 polypropylene Polymers 0.000 claims description 7
- 229960003135 donepezil hydrochloride Drugs 0.000 claims description 6
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012982 microporous membrane Substances 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 238000005576 amination reaction Methods 0.000 claims description 4
- 150000001735 carboxylic acids Chemical class 0.000 claims description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 claims description 2
- 229960002024 galantamine hydrobromide Drugs 0.000 claims description 2
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 claims description 2
- 229960000967 memantine hydrochloride Drugs 0.000 claims description 2
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 229960003565 tacrine hydrochloride Drugs 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 7
- 239000012466 permeate Substances 0.000 abstract description 4
- 230000001464 adherent effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 44
- 210000003491 skin Anatomy 0.000 description 28
- 230000004907 flux Effects 0.000 description 22
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 18
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 16
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000000853 adhesive Substances 0.000 description 13
- 230000001070 adhesive effect Effects 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 229960003530 donepezil Drugs 0.000 description 8
- 229920000139 polyethylene terephthalate Polymers 0.000 description 7
- 239000005020 polyethylene terephthalate Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 150000002334 glycols Chemical class 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 5
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 5
- 239000001069 triethyl citrate Substances 0.000 description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 5
- 235000013769 triethyl citrate Nutrition 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001567 vinyl ester resin Polymers 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- WZZOUUXJVMQXMR-UHFFFAOYSA-N 2,2-diethyldecanedioic acid Chemical compound CCC(CC)(C(O)=O)CCCCCCCC(O)=O WZZOUUXJVMQXMR-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- MMSGPUZNNKBAMN-UHFFFAOYSA-N 3-ethyl-4-hydroxyheptane-2,3,4-tricarboxylic acid Chemical compound CCC(C(O)=O)C(O)(C(O)=O)C(CC)(CC)C(O)=O MMSGPUZNNKBAMN-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- IYNRVIKPUTZSOR-HWKANZROSA-N ethenyl (e)-but-2-enoate Chemical compound C\C=C\C(=O)OC=C IYNRVIKPUTZSOR-HWKANZROSA-N 0.000 description 1
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002648 laminated material Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79829606P | 2006-05-08 | 2006-05-08 | |
| US60/798,296 | 2006-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090009951A true KR20090009951A (ko) | 2009-01-23 |
Family
ID=38667540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087029711A Ceased KR20090009951A (ko) | 2006-05-08 | 2006-12-25 | 항치매제를 포함하는 경피 흡수 제제 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7858114B2 (enExample) |
| EP (1) | EP2016939B1 (enExample) |
| JP (1) | JP5122445B2 (enExample) |
| KR (1) | KR20090009951A (enExample) |
| CN (1) | CN101460156B (enExample) |
| AU (1) | AU2006343077B2 (enExample) |
| BR (1) | BRPI0621655A2 (enExample) |
| CA (1) | CA2651596C (enExample) |
| ES (1) | ES2466647T3 (enExample) |
| IL (1) | IL195174A0 (enExample) |
| IN (1) | IN266817B (enExample) |
| MY (1) | MY149152A (enExample) |
| NO (1) | NO20084614L (enExample) |
| NZ (1) | NZ572809A (enExample) |
| RU (1) | RU2428179C2 (enExample) |
| WO (1) | WO2007129427A1 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012002640A3 (ko) * | 2010-06-30 | 2012-04-12 | 엔에이엘 파마슈티칼즈 엘티디. | 도네페질을 함유하는 경피흡수제제 |
| KR20120128606A (ko) * | 2009-12-22 | 2012-11-27 | 아시노 아게 | 리바스티그민 또는 그의 유도체 투여용 경피 치료 시스템 |
| KR101239150B1 (ko) * | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
| KR101325104B1 (ko) * | 2009-09-16 | 2013-11-07 | 주식회사 삼양바이오팜 | 경피 투여 제형 및 그 제조 방법 |
| KR20140031639A (ko) * | 2012-09-05 | 2014-03-13 | 주식회사 한독 | 피부 자극이 감소된 메만틴 경피전달 시스템 |
| US10195408B2 (en) | 2014-02-20 | 2019-02-05 | Nal Pharmaceutical Group Limited | Transdermal drug delivery system containing donepezil |
| KR20190032512A (ko) * | 2016-07-27 | 2019-03-27 | 코리움 인터네셔널, 인크. | 도네페질 경피 전달 시스템 |
| KR20190032551A (ko) * | 2016-07-27 | 2019-03-27 | 코리움 인터네셔널, 인크. | 메만틴 경피 송달 시스템 |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101573115B (zh) * | 2006-12-01 | 2012-06-06 | 日东电工株式会社 | 抑制含有多奈哌齐的贴剂着色的方法、及降低多奈哌齐类似物的生成量的方法 |
| KR101408488B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법 |
| CA2719605C (en) * | 2008-03-25 | 2016-07-12 | Teikoku Seiyaku Co., Ltd. | Transdermally absorbable preparation |
| US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| EP2279739B2 (en) * | 2008-05-30 | 2018-02-28 | Nitto Denko Corporation | Donepezil-containing patch preparation and packaging thereof |
| BRPI0912099A2 (pt) * | 2008-05-30 | 2015-10-06 | Eisai R&D Man Co Ltd | preparação percutaneamente absorvível |
| US20100080842A1 (en) * | 2008-09-30 | 2010-04-01 | Jianye Wen | Transdermal extended-delivery donepezil compositions and methods for using the same |
| US8858983B2 (en) | 2009-04-30 | 2014-10-14 | Medtronic, Inc. | Antioxidants and antimicrobial accessories including antioxidants |
| KR20120101704A (ko) * | 2009-12-16 | 2012-09-14 | 고토 다케시 | 항인지증 약물의 경피흡수제제 |
| JP2012236773A (ja) * | 2009-12-16 | 2012-12-06 | Goto Takeshi | 抗認知症薬物の経皮吸収製剤 |
| TW201143817A (en) * | 2009-12-16 | 2011-12-16 | Goto Takeshi | Transdermally absorbed preparation of anti-dementia drug |
| US10076502B2 (en) | 2009-12-22 | 2018-09-18 | Luye Pharma Ag | Transdermal therapeutic system for administering rivastigmine or derivatives thereof |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| RS54173B1 (sr) | 2010-12-14 | 2015-12-31 | Acino Ag | Transdermalni terapijski sistem za davanje aktivne supstance |
| US8911427B2 (en) * | 2010-12-28 | 2014-12-16 | Medtronic, Inc. | Therapeutic agent reservoir delivery system |
| TWI433904B (zh) * | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | 多奈哌齊經皮貼片 |
| KR101054317B1 (ko) | 2011-01-28 | 2011-08-08 | 신신제약 주식회사 | 리바스티그민을 함유하는 경피흡수제제 |
| KR101317158B1 (ko) | 2011-02-18 | 2013-10-15 | 조선대학교산학협력단 | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
| BR112013029945A2 (pt) * | 2011-05-20 | 2017-01-31 | Sk Chemicals Co Ltd | emplastro contendo rivastigmina |
| KR101395557B1 (ko) * | 2011-08-25 | 2014-05-16 | 아이큐어 주식회사 | 경피 흡수 제제 및 그 제조방법 |
| KR102171152B1 (ko) * | 2012-12-13 | 2020-10-29 | 하. 룬드벡 아크티에셀스카브 | 보르티옥세틴 및 도네페질을 포함하는 조성물 |
| JP6151935B2 (ja) * | 2013-03-11 | 2017-06-21 | 日東電工株式会社 | 経皮吸収促進用組成物および貼付製剤 |
| EP3310348B1 (en) | 2015-06-22 | 2020-08-05 | Corium, Inc. | Transdermal adhesive composition comprising a poorly soluble therapeutic agent |
| JP6148416B2 (ja) | 2015-06-29 | 2017-06-14 | 積水化学工業株式会社 | コアシェル構造体及び外用剤 |
| US10966936B2 (en) | 2015-12-30 | 2021-04-06 | Corium, Inc. | Systems comprising a composite backing and methods for long term transdermal administration |
| CA3028436A1 (en) | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| WO2018022814A1 (en) * | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| RU2748651C2 (ru) * | 2017-02-28 | 2021-05-28 | Кимберли-Кларк Ворлдвайд, Инк. | Синергическая композиция для сохранения здорового баланса микрофлоры |
| CN108096690B (zh) * | 2017-04-07 | 2019-08-20 | 杭州多泰科技有限公司 | 一种诱导循环肿瘤细胞转移的可移植支架的制备方法 |
| KR102033686B1 (ko) | 2017-05-19 | 2019-10-18 | 보령제약 주식회사 | 도네페질을 함유하는 마이크로니들 경피 패치 |
| CN111132669A (zh) * | 2017-07-26 | 2020-05-08 | 考里安公司 | 具有带溶剂填充孔的微孔膜的透皮递送系统 |
| CA3085342A1 (en) | 2017-12-13 | 2019-06-20 | Corium, Inc. | Method for depot creation during transdermal drug delivery |
| US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| CN108926549A (zh) * | 2018-09-27 | 2018-12-04 | 安徽安科余良卿药业有限公司 | 卡巴拉汀凝胶贴膏及其制备方法 |
| US20220175812A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| KR102489860B1 (ko) * | 2021-09-02 | 2023-01-19 | 동아에스티 주식회사 | 메만틴 에난트산염을 포함하는 치매 치료용 경피흡수 제제 |
| CN115957200A (zh) * | 2023-02-23 | 2023-04-14 | 广州新济药业科技有限公司 | 一种美金刚透皮贴剂及制备方法 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI921121A0 (fi) | 1989-09-14 | 1992-03-16 | Cygnus Research Corp | Transdermal doseringsanordning med foerdroejd start. |
| JP2977254B2 (ja) | 1990-09-04 | 1999-11-15 | 積水化学工業株式会社 | 経皮吸収貼付剤 |
| US5273756A (en) | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
| JPH06199659A (ja) * | 1992-10-28 | 1994-07-19 | Hisamitsu Pharmaceut Co Inc | 経皮治療用装置 |
| ATE149349T1 (de) * | 1993-06-25 | 1997-03-15 | Alza Corp | Einarbeitung eines poly-n-vinylamids in ein transdermales system |
| FR2717689B1 (fr) * | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base de copolymère styrène-isoprène-styrène. |
| US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
| DE19533772C1 (de) * | 1995-09-12 | 1998-01-02 | Hexal Ag | Tacrin/Selegilin-Pflaster |
| DE19653605C2 (de) * | 1996-12-20 | 2002-11-28 | Roehm Gmbh | Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems |
| JPH10315016A (ja) | 1997-05-15 | 1998-12-02 | Nissan Diesel Motor Co Ltd | チャック装置 |
| JP3987655B2 (ja) * | 1998-03-03 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
| DE19918106A1 (de) * | 1999-04-22 | 2000-10-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern |
| GB9917290D0 (en) * | 1999-07-22 | 1999-09-22 | Glaxo Wellcome Spa | Pharmaceutical composition |
| DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| FR2814368B1 (fr) * | 2000-09-26 | 2004-05-07 | Pf Medicament | Preparation pharmaceutique a base d'oxans |
| JP4057418B2 (ja) * | 2000-11-07 | 2008-03-05 | 久光製薬株式会社 | 経皮吸収型製剤 |
| DE10060550C1 (de) | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
| JP4394443B2 (ja) * | 2001-10-17 | 2010-01-06 | 久光製薬株式会社 | 経皮吸収型製剤 |
| DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| JP4274951B2 (ja) * | 2004-01-07 | 2009-06-10 | 久光製薬株式会社 | 異型断面繊維を使用した支持体を有するテーピング型貼付剤 |
| JPWO2005115355A1 (ja) * | 2004-05-28 | 2008-03-27 | 久光製薬株式会社 | 貼付製剤 |
-
2006
- 2006-12-25 ES ES06835183.2T patent/ES2466647T3/es active Active
- 2006-12-25 JP JP2008514366A patent/JP5122445B2/ja active Active
- 2006-12-25 KR KR1020087029711A patent/KR20090009951A/ko not_active Ceased
- 2006-12-25 NZ NZ572809A patent/NZ572809A/en not_active IP Right Cessation
- 2006-12-25 WO PCT/JP2006/325813 patent/WO2007129427A1/ja not_active Ceased
- 2006-12-25 MY MYPI20084469A patent/MY149152A/en unknown
- 2006-12-25 BR BRPI0621655-2A patent/BRPI0621655A2/pt not_active IP Right Cessation
- 2006-12-25 CN CN200680054495XA patent/CN101460156B/zh active Active
- 2006-12-25 IN IN2543MUN2008 patent/IN266817B/en unknown
- 2006-12-25 EP EP06835183.2A patent/EP2016939B1/en active Active
- 2006-12-25 CA CA2651596A patent/CA2651596C/en active Active
- 2006-12-25 AU AU2006343077A patent/AU2006343077B2/en active Active
- 2006-12-25 RU RU2008148131/15A patent/RU2428179C2/ru not_active IP Right Cessation
-
2007
- 2007-05-07 US US11/797,722 patent/US7858114B2/en not_active Expired - Fee Related
-
2008
- 2008-10-31 NO NO20084614A patent/NO20084614L/no not_active Application Discontinuation
- 2008-11-09 IL IL195174A patent/IL195174A0/en unknown
-
2010
- 2010-11-17 US US12/948,252 patent/US20110059141A1/en not_active Abandoned
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101325104B1 (ko) * | 2009-09-16 | 2013-11-07 | 주식회사 삼양바이오팜 | 경피 투여 제형 및 그 제조 방법 |
| US8864727B2 (en) | 2009-09-16 | 2014-10-21 | Samyang Biopharmaceuticals Corporation | Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system |
| KR20120128606A (ko) * | 2009-12-22 | 2012-11-27 | 아시노 아게 | 리바스티그민 또는 그의 유도체 투여용 경피 치료 시스템 |
| US9155711B2 (en) | 2010-06-30 | 2015-10-13 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
| CN103096882A (zh) * | 2010-06-30 | 2013-05-08 | 纳尔制药有限公司 | 含有多奈哌齐的经皮吸收制剂 |
| WO2012002640A3 (ko) * | 2010-06-30 | 2012-04-12 | 엔에이엘 파마슈티칼즈 엘티디. | 도네페질을 함유하는 경피흡수제제 |
| KR101239150B1 (ko) * | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
| WO2013129813A1 (ko) * | 2012-02-28 | 2013-09-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
| KR20140031639A (ko) * | 2012-09-05 | 2014-03-13 | 주식회사 한독 | 피부 자극이 감소된 메만틴 경피전달 시스템 |
| US10195408B2 (en) | 2014-02-20 | 2019-02-05 | Nal Pharmaceutical Group Limited | Transdermal drug delivery system containing donepezil |
| KR20190032512A (ko) * | 2016-07-27 | 2019-03-27 | 코리움 인터네셔널, 인크. | 도네페질 경피 전달 시스템 |
| KR20190032551A (ko) * | 2016-07-27 | 2019-03-27 | 코리움 인터네셔널, 인크. | 메만틴 경피 송달 시스템 |
| KR20220082098A (ko) * | 2016-07-27 | 2022-06-16 | 코리움, 인크. | 도네페질 경피 전달 시스템 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2016939A1 (en) | 2009-01-21 |
| CN101460156A (zh) | 2009-06-17 |
| BRPI0621655A2 (pt) | 2011-12-20 |
| ES2466647T3 (es) | 2014-06-10 |
| AU2006343077A1 (en) | 2007-11-15 |
| US7858114B2 (en) | 2010-12-28 |
| CA2651596C (en) | 2014-03-25 |
| IN266817B (enExample) | 2015-06-03 |
| AU2006343077B2 (en) | 2012-11-08 |
| MY149152A (en) | 2013-07-15 |
| RU2428179C2 (ru) | 2011-09-10 |
| JP5122445B2 (ja) | 2013-01-16 |
| HK1130175A1 (en) | 2009-12-24 |
| NO20084614L (no) | 2009-02-06 |
| IL195174A0 (en) | 2009-08-03 |
| US20070259028A1 (en) | 2007-11-08 |
| CN101460156B (zh) | 2011-06-08 |
| NZ572809A (en) | 2011-02-25 |
| EP2016939B1 (en) | 2014-03-19 |
| US20110059141A1 (en) | 2011-03-10 |
| RU2008148131A (ru) | 2010-06-20 |
| EP2016939A4 (en) | 2013-01-09 |
| CA2651596A1 (en) | 2007-11-15 |
| JPWO2007129427A1 (ja) | 2009-09-17 |
| WO2007129427A1 (ja) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20090009951A (ko) | 항치매제를 포함하는 경피 흡수 제제 | |
| JP5800715B2 (ja) | 抗認知症薬物の経皮吸収製剤 | |
| CN102026664B (zh) | 稳定化β阻断剂的组合物以及含有该组合物的透皮吸收制剂 | |
| KR101617927B1 (ko) | 도네페질 경피 패치제 | |
| US9622986B2 (en) | Percutaneous absorption preparation containing donepezil, and method for preparing same | |
| KR20120102747A (ko) | 항인지증 약물의 경피흡수제제 | |
| JP7688036B2 (ja) | アゴメラチンを含有する経皮治療システム | |
| HK1130175B (en) | Tansdermally absorbable preparation comprising anti-dementia agent | |
| MX2008014151A (es) | Preparaciones de absorcion percutanea de drogas contra demencia. | |
| HK1179184A (en) | Transdermally absorbed preparation of anti-dementia drug | |
| HK1179184B (en) | Transdermally absorbed preparation of anti-dementia drug | |
| WO2014159778A1 (en) | Transdermal drug delivery system containing fentanyl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20081204 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20111017 Comment text: Request for Examination of Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130524 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20131101 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130524 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |